{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:11:23Z","timestamp":1761156683790,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["714312"],"award-info":[{"award-number":["714312"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NWO","award":["Vidi"],"award-info":[{"award-number":["Vidi"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1893-z","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T17:00:48Z","timestamp":1557248448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-2693","authenticated-orcid":false,"given":"L. E.","family":"Burgers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. F.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H. M.","family":"van der Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"12","key":"1893_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/ard.54.12.944","volume":"54","author":"P Emery","year":"1995","unstructured":"Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54(12):944\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1893_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1893_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1893_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/art.30129","volume":"63","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. American College of Rheumatology\/European League Against Rheumatism preliminary definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573\u201386.","journal-title":"Arthritis Rheum"},{"key":"1893_CR5","doi-asserted-by":"crossref","unstructured":"Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17(1) Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4522973\/\n                    \n                  .","DOI":"10.1186\/s13075-015-0707-1"},{"issue":"6","key":"1893_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EMA, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73(6):1027\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1893_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barr\u00e9 E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1893_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","volume":"74","author":"TWJ Huizinga","year":"2015","unstructured":"Huizinga TWJ, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1893_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/ard.2010.141234","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek NB, G\u00fcler-Y\u00fcksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJSM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70(6):1039\u201346.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1893_CR10","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/art.24661","volume":"60","author":"D van der Woude","year":"2009","unstructured":"van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes REM, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60(8):2262\u201371.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1893_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/14397595.2013.854079","volume":"24","author":"N Nishimoto","year":"2014","unstructured":"Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, et al. Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17\u201325.","journal-title":"Mod Rheumatol"},{"issue":"19","key":"1893_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781\u201392.","journal-title":"N Engl J Med"},{"issue":"5","key":"1893_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","volume":"75","author":"S Ajeganova","year":"2015","unstructured":"Ajeganova S, van Steenbergen HW, van Nies JAB, Burgers LE, Huizinga TWJ, van der Helm-van Mil AHM. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2015. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-207080\n                    \n                  .","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"1893_CR14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3899\/jrheum.110394","volume":"38","author":"LH van Tuyl","year":"2011","unstructured":"van Tuyl LH, Smolen JS, Wells GA, Scholte-Voshaar M, Hoogland W, Boers M. Patient perspective on remission in rheumatoid arthritis. J Rheumatol. 2011;38(8):1735\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"1893_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1136\/ard.2008.105577","volume":"69","author":"R O\u2019Mahony","year":"2010","unstructured":"O\u2019Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69(10):1823\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1893_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1893_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/ard.2010.136556","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek NB, van der v d KSM, G\u00fcler-Y\u00fcksel M, van GJHLM, Han KH, Kerstens PJSM, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70(2):315\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1893_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","volume":"77","author":"G\u00fcl\u015fah Akdemir","year":"2017","unstructured":"Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van OM, van GJHLM, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2017. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211375\n                    \n                  .","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"1893_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","volume":"50","author":"DPC de Rooy","year":"2011","unstructured":"de Rooy DPC, van der Linden MPM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM. Predicting arthritis outcomes\u2014what can be learned from the Leiden Early Arthritis Clinic? Rheumatology. 2011;50(1):93\u2013100.","journal-title":"Rheumatology."},{"key":"1893_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","volume":"18","author":"L Heimans","year":"2016","unstructured":"Heimans L, Akdemir G, Boer KVCW, Goekoop-Ruiterman YP, Molenaar ET, van Groenendael JHLM, et al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res Ther. 2016;18:23.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1893_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7326\/M15-0919","volume":"164","author":"IM Markusse","year":"2016","unstructured":"Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YPM, van Groenendael JHLM, Han KH, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016;164(8):523\u201331.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1893_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/rheumatology\/ker516","volume":"51","author":"D van der Woude","year":"2012","unstructured":"van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJSM, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology. 2012;51(6):1120\u20138.","journal-title":"Rheumatology."},{"issue":"8","key":"1893_CR23","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2012-202289","volume":"72","author":"JAB van Nies","year":"2013","unstructured":"van Nies JAB, Brouwer E, van Gaalen FA, Allaart CF, Huizinga TWJ, Posthumus MD, et al. Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. Ann Rheum Dis. 2013;72(8):1295\u2013301.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1893_CR24","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/art.11156","volume":"48","author":"M Boers","year":"2003","unstructured":"Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1771\u20134.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1893-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1893-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:18:14Z","timestamp":1588720694000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1893-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1893-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol of the IMPROVED study and the EAC cohort were approved by the local medical ethical committee of the Leiden University Medical Center. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"115"}}